MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.680
-0.020
-1.18%
After Hours: 1.690 +0.01 +0.60% 19:59 01/21 EST
OPEN
1.660
PREV CLOSE
1.700
HIGH
1.740
LOW
1.660
VOLUME
631.19K
TURNOVER
--
52 WEEK HIGH
8.60
52 WEEK LOW
1.360
MARKET CAP
53.93M
P/E (TTM)
-0.9395
1D
5D
1M
3M
1Y
5Y
15 Worst Stock Picks of Cathie Wood
In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the ...
Insider Monkey · 1d ago
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares gained 37.2% to $6.75 after the company eeceived FDA Breakthrough Device Designation for the treatment of chronic chemo induced peripheral neuropathy with its wearable neurostimulation technology.
Benzinga · 4d ago
NeuroMetrix, Mainz lead healthcare gainers; Dyne, Allarity among losers
Gainers: NeuroMetrix (NASDAQ:NURO) +39%. Mainz Biomed MYNZ +26%. Immuron (NASDAQ:IMRN) +22%. . Cardiol Therapeutics CRDL +15%. Pluristem Therapeutics PSTI +13%. Losers: Dyne Therapeutics DYN -17%. Allarity Therapeutics (NASDAQ:ALLR) -15%. Molecular Partner...
Seekingalpha · 4d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 4d ago
PSTI, NES and VORB among mid-day movers
Gainers: Splash Beverage Group (NYSE:SBEV) +37%. Virgin Orbit Holdings (NASDAQ:VORB) +26%. TSR (NASDAQ:TSRI) +27%. Accolade (NASDAQ:ACCD) +26%. BARK (NYSE:BARK) +25%. Veru (NASDAQ:VERU) +22%. Nutriband (NASDAQ:NTRB) +22%. Nuverra Environmental Solutions (N...
Seekingalpha · 01/11 17:39
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
Benzinga · 01/11 09:52
MRIN, NRIX and ELYM among mid-day movers
Gainers: Bone Biologics (OTCPK:BBLG) +82%. Zynga (NASDAQ:ZNGA) +43%. RxSight (NASDAQ:RXST) +34%. Olink (NASDAQ:OLK) +31%. Apria (NASDAQ:APR) +26%. Molecular (NASDAQ:MOLN) +25%. iRhythm Technologies (NASDAQ:IRTC) +25%. BioCryst (NASDAQ:BCRX) +21%. G Medical...
Seekingalpha · 01/10 17:44
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
Benzinga · 01/10 17:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PSTI stock price target is 7.88 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average7.88
Low3.000
Current 1.680
EPS
Actual
Estimate
-0.39-0.29-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 78
Institutional Holdings: 4.52M
% Owned: 14.09%
Shares Outstanding: 32.10M
TypeInstitutionsShares
Increased
20
696.09K
New
3
68.52K
Decreased
16
669.50K
Sold Out
8
231.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Director
Rami Levi
Director
Varda Shalev
Independent Director
Doron Birger
Independent Director
Mark Germain
Independent Director
Moria Kwiat
Independent Director
Maital Shemesh-Rasmussen
Independent Director
Doron Shorrer
No Data
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.